Reaction
Blood Iron Abnormal reporting signals
As of the last recalculation, Blood Iron Abnormal appears in 969 FAERS reports alongside 28 co-occurring drug terms. The strongest observed disproportionality signal is SULFASALAZINE (PRR 143.3).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Sulfasalazine | 340 | 143.3 | 143.9 |
| Azathioprine | 359 | 138.4 | 139.0 |
| Leflunomide | 357 | 115.4 | 115.8 |
| Tocilizumab | 348 | 101.7 | 102.0 |
| Certolizumab Pegol | 344 | 97.2 | 97.5 |
| Hydroxychloroquine | 241 | 92.0 | 92.3 |
| Hydroxychloroquine Sulfate | 209 | 62.6 | 62.7 |
| Infliximab | 330 | 48.7 | 48.8 |
| Golimumab | 105 | 29.4 | 29.4 |
| Deferasirox | 32 | 26.8 | 26.8 |
| Methotrexate Sodium | 356 | 24.3 | 24.3 |
| Methotrexate | 308 | 22.6 | 22.6 |
| Abatacept | 123 | 21.7 | 21.7 |
| Etanercept | 369 | 20.8 | 20.8 |
| Cyclosporine | 96 | 20.5 | 20.5 |
| Epoetin Alfa | 11 | 20.2 | 20.2 |
| Adalimumab | 398 | 19.8 | 19.8 |
| Mycophenolate Mofetil | 104 | 18.3 | 18.3 |
| Mycophenolate Mofetil Hydrochloride | 104 | 18.3 | 18.3 |
| Tofacitinib Citrate | 11 | 18.2 | 18.2 |
| Infliximab-Dyyb | 18 | 13.5 | 13.5 |
| Ravulizumab | 7 | 11.2 | 11.2 |
| Avapritinib | 6 | 10.7 | 10.7 |
| Dronedarone | 4 | 8.5 | 8.5 |
| Ruxolitinib | 25 | 7.7 | 7.7 |
| Naltrexone Hydrochloride And Bupropion Hydrochloride | 3 | 7.6 | 7.6 |
| Diroximel Fumarate | 4 | 7.2 | 7.2 |
| Methoxy Polyethylene Glycol-Epoetin Beta | 3 | 5.9 | 5.9 |